Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 15, 2020
Daily News
June 15, 2020
- Nearly 80% of Clinics See Increase in Long-Term Prescriptions amid COVID-19: JMA Survey
June 15, 2020
- 26 Japan Drug Makers Generate 56.4% of Sales Overseas in FY2019, Shire Buy Gives Boost: Tally
June 15, 2020
- MHLW Starts Inviting Coronavirus Vaccine Developers after 2nd Extra Budget Passed
June 15, 2020
- Otsuka’s ADHD Med Hits Primary Goal in US PIII Trials
June 15, 2020
- Takeda, Mitsubishi-UBS Asset JV to Collaborate in Shonan iPark Operations
June 15, 2020
- PeptiDream, US Merck Link Up to Develop COVID-19 Treatment
June 15, 2020
- Daiichi Sankyo to Kickstart COVID-19 Vaccine Development
June 15, 2020
- AbbVie Files Rinvoq for Psoriatic Arthritis in Japan
June 15, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…